A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimumab and MTX
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Sarilumab (Primary) ; Adalimumab; Etanercept; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RA-COMPARE; SARIL-RA-COMPARE
- Sponsors Sanofi
- 11 Jan 2022 Trial has been completed in Norway, according to European Clinical Trials Database record.
- 15 Jul 2019 Results (n=2887) of post-hoc pooled analysis of eight studies (MOBILITY, NCT01061736; TARGET, NCT01709578; ASCERTAIN, NCT01768572; MONARCH, NCT02332590; ACT11575, NCT01217814; ONE, NCT02121210; COMPARE, NCT01764997; and EASY, NCT02057250) and one open label extension (EXTEND; NCT01146652) assessing long-term safety up to 7 years follow up of sarilumab in rheumatoid arthritis patients, published in the Rheumatology.
- 21 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.